Skip to main navigation Skip to search Skip to main content

Characteristics and outcomes of patients with V299L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors

Research output: Contribution to journal › Letter › peer-review

Original languageEnglish (US)
Pages (from-to)3382-3383
Number of pages2
JournalBlood
Volume120
Issue number16
DOIs
StatePublished - Oct 18 2012

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

MD Anderson CCSG core facilities

  • Clinical Trials Office

Cite this